MedTrace Logo

Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease

NCT04277247 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-05-17

No results posted yet for this study

Summary

To study the effects of Botulinum toxin type A (BTXA) in the treatment of foot dystonia-associated pain in Parkinson's disease

Conditions

  • Dystonia Disorder
  • Parkinson Disease

Interventions

DRUG

Botulinum toxin type A

A standardized dose will be injected in each muscle: 25 Units of BTXA in the extensor hallucis longus in 1 site, 50 Units of BTXA in the flexor digitorum brevis in 2 sites and 25 Units of BTXA in the tibialis posterior in 1 site.

DRUG

Placebo

0.9% saline placebo injection

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • University of Calgary

    lead OTHER

Principal Investigators

  • Veronica Bruno, MD, MPH · University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-12
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04277247 on ClinicalTrials.gov